The price of Atossa Therapeutics Inc (NASDAQ: ATOS) closed at $1.66 in the last session, down -6.21% from day before closing price of $1.77. On the day, 1998158 shares were traded.
Ratios:
We take a closer look at ATOS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.61 and its Current Ratio is at 17.61. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on January 26, 2018, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 10 ’24 when Finn Jonathan bought 25,000 shares for $1.77 per share. The transaction valued at 44,250 led to the insider holds 25,000 shares of the business.
WEAVER GREGORY L sold 50,000 shares of ATOS for $32,500 on Nov 15 ’23. The Former EVP, CFO, & Director now owns 55 shares after completing the transaction at $0.65 per share.
Stock Price History:
Over the past 52 weeks, ATOS has reached a high of $2.31, while it has fallen to a 52-week low of $0.59.
Shares Statistics:
A total of 125.30M shares are outstanding, with a floating share count of 125.25M. Insiders hold about 0.02% of the company’s shares, while institutions hold 19.14% stake in the company.
Earnings Estimates
The company has Atossa Therapeutics, Inc. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $18.21, with high estimates of $113.99 and low estimates of $86.50.
Analysts are recommending an EPS of between $Utilities and $Industrials for the fiscal current year, implying an average EPS of $Industrials.
